^Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
^Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
^Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. European Journal of Cancer. October 2008, 44 (15): 2178–84. PMID 18676140. doi:10.1016/j.ejca.2008.06.036.
^Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Journal of Clinical Oncology. October 2005, 23 (28): 6854–64. PMID 16192577. doi:10.1200/JCO.2005.17.186.
.
